UK-based pharmaceutical giant GlaxoSmithKline has partnered with South San Francisco-based Verily to create Galvani Bioelectronics – a joint venture to develop implantable bioelectric medicines, a branch of medicine that works to fight diseases by targeting electrical signals in the body.
Galvani, owned 55 percent by GSK and 45 percent by Verily (formerly known as Google Life Sciences) will have...
GlaxoSmithKline has launched the ResearchKit app that it told Buzzfeed it was working on more than a year ago, making it the first pharma company to get a ResearchKit study off the ground. The study is called PARADE, which the company says stands for Patient Rheumatoid Arthritis Data in the Real World.
"We are the first in our industry to use Apple’s ResearchKit as part of our research, this time...
As we do every quarter, MobiHealthNews has rounded up our Q1 2016 coverage into a handful of longform stories. This section is on pharma. Skip ahead using these links to read Q1 digital health news roundups about providers, payers, M&A and funding.
Novartis
Novartis announced a partnership with Qualcomm Life, a subsidiary of Qualcomm, to develop a connected version of its inhaler, Breezhaler...
More and more, pharma companies are making real bets in digital health, and reorganizing their businesses to put some power behind those efforts. The space is, in some ways, quieter than it was this time last year, but there’s reason to believe that quiet is a calm before a storm of activity, driven more by pharma’s tendency to keep early-stage projects close to the chest than by a lack of...
Digital smoking cessation company 2Morrow has partnered with GlaxoSmithKline, makers of Nicoderm patches, to offer the company’s Nicoderm CQ Patch to smokers who complete 2morrow’s cessation program.
2Morrow’s smoking cessation app, called SmartQuit, is based on acceptance and commitment therapy, or an ACT-based program, that "focuses on increasing one’s willingness to accept the physical, mental...
According to a report in Bloomberg, GlaxoSmithKline is in talks with Qualcomm to create a new joint venture to develop medical technology. Financial Times added in its report that the JV could be worth up to $1 billion.
Very little information about the prospective partnership is available, but it makes sense for both companies: Qualcomm has already teamed up with both Roche and Novartis on major...
GSK's Ellipta inhaler
GlaxoSmithKline and Madison, Wisconsin-based Propeller Health announced a partnership today in which Propeller will develop and manufacture a custom sensor for GSK's Ellipta inhaler for COPD patients.
Like the other inhaler sensors Propeller has developed, the device will record when and where the patient uses the inhaler and wirelessly transmit that information to GSK ...
Over the last two years, big pharma has gotten behind the idea of smartphone-connected inhalers for asthma and COPD in a big way. Two acquisitions, a $3 million investment, and a number of pilot and partnership deals have shown clearly that the space is of interest. (MobiHealthNews is helping to put on two pharma-related events at the mHealth Summit next week -- be sure to join us if you'll be in...
MedWatcher, from Epidemico.
We've written before about Epidemico, a startup that grew out of the Boston Children's Hospital's work on combing social media for medical and health data. Today at the Health 2.0 conference in Santa Clara, California, Greg Powell, director of pharmacovigilance at GlaxoSmithKline, talked about how the pharma company uses the data it collects from its partnership...
Madison, Wisconsin-based Propeller Health has secured two new FDA clearances for new sensors that are designed to work with two particular inhalers on the market: the Diskus inhaler from GlaxoSmithKline and the Respimat inhaler from Boehringer Ingelheim. Unlike previous FDA clearances for Propeller, the new clearances actually allow Propeller to market its new devices as improving — not just...
.jpeg?itok=HF3iI7dj "Person answering their front door and getting a delivery from another person")
